SEPTInvestingStart Free

BRTX 8-K: Board change

Filed with the SEC on · accession 0001213900-26-119019

BRTX filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved -4.5% by the first close after the filing.

Summary of the filing

Two directors, Esha Randhawa and Jatinder Dhaliwal, resigned from BioRestorative Therapies' board on November 5-6, 2026, and David Jenkins was appointed as a Class III director on November 10, 2026, filling the vacancy and taking on committee chair roles.

For details, click here →How to read a 8-K →

Key details

Monthly cash fee for David Jenkins as non-employee directorCAD 2K
RegistrantBioRestorative Therapies, Inc.
Company where david jenkins serves as directorAkanda Corp.
Company where david jenkins served as interim ceo/cfoKiaro Holdings Corp.
Company where david jenkins served as directorBinovi Technologies Corp.
Company where david jenkins served as directorLevitee Labs Inc.
Company where david jenkins served as directorPontus Protein Ltd.
Company where david jenkins serves as directorBoundary Gold & Copper Mining Ltd.
Company where david jenkins serves as directorMontego Resources Inc.
Company where david jenkins serves as directorQuantum Battery Metals Corp.
DirectorEsha Randhawa
DirectorJatinder Dhaliwal
Class iii director, audit committee member, chair of compensation and nominating/governance committeesDavid Jenkins
Director, audit committee memberDonald J. Currie
Director, audit committee chairSteven Brown

How BRTX stock reacted

Close before

$1.57

Nov 11, 2026

First close after

-4.46%

$1.50

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for BRTX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BRTX?

Click here

Frequently asked questions

What did BRTX file with the SEC on Nov 12, 2026?

BRTX filed a 8-K (Board change). Two directors, Esha Randhawa and Jatinder Dhaliwal, resigned from BioRestorative Therapies' board on November 5-6, 2026, and David Jenkins was appointed as a Class III director on November 10, 2026, filling the vacancy and taking on committee chair roles.

What does a board change mean for BRTX stock?

Not always. A planned retirement with a successor is usually calm; a sudden departure “effective immediately”, especially of a CFO or near results, often worries investors.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did BRTX stock react to this filing?

BRTX closed at $1.57 before the filing and $1.50 on Nov 12, 2026 (-4.46%).

Other BRTX SEC filings

Get alerts when BRTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
BRTX overviewBRTX analysisBRTX newsLatest SEC filings